Acura Pharmaceuticals Provides Development Update on Its

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology

PALATINE, IL --(Marketwired - December 17, 2015) - Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that's it is advancing its lead LIMITX™ oral abuse deterrent drug candidate using the opioid hydromorphone HCl (LIMITX Hydromorphone) into clinical testing. LIMITX is designed to retard the release of its active ingredient as more and more tablets are orally consumed. The Company expects to submit an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) before the end of 2015. Unless questioned by the FDA, the IND will become effective 30-days after submission and the Company will be eligible to commence clinical testing.

The initial clinical trial proposed for LIMITX Hydromorphone, Study AP-LTX-400, will be a Phase 1 exploratory pharmacokinetic study to evaluate the plasma absorption of hydromorphone from orally administered tablets in the fasted state. Study AP-LTX-400 will target to complete approximately 48 healthy subjects in two separate cohorts, with 24 subjects in each cohort. For safety, all subjects will receive a naltrexone block prior to dosing to blunt any serious adverse effects that may result from the doses of hydromorphone.

Subjects in Cohort 1 will be further randomized into three dosage groups taking either one, two or three 2mg hydromorphone tablets. Each Cohort 1 subject will take two different test formulations of LIMITX Hydromorphone and DILAUDID brand of hydromorphone HCl. The objective of Cohort 1 will be to determine if the LIMITX Hydromorphone test products are delivering the appropriate amount of hydromorphone into the blood stream to treat pain. Additionally, Cohort 1 may begin assessing the extent that the release of hydromorphone active ingredient from the LIMITX Hydromorphone tablets is retarded as the dose level increases.

Following the results of Cohort 1, Cohort 2 subjects will be randomized into three dosage groups taking four, six or eight 2mg hydromorphone tablets. Each Cohort 2 subject will take one test formulation of LIMITX Hydromorphone selected based on the results of Cohort 1 and DILAUDID. The objective of Cohort 2 will be to further explore the extent the release of hydromorphone active ingredient from the LIMITX Hydromorphone tablets is retarded as the dose level increases to abusive levels. A safety assessment of LIMITX Hydromorphone will be made from both study cohorts.

Acura expects topline study results from Study AP-LTX-400 to be available in the first half of 2016.

"Study AP-LTX-400 will be a tremendous milestone in the development of the LIMITX Technology," said Dr. Al Brzeczko, Acura's Vice President of Technical Affairs and co-inventor of the LIMITX Technology. "We expect to gain insight into how LIMITX works in patients and have designed the study to guide us to adjusting the formulation if needed."

Bob Jones, Acura's President and CEO added, "Acura is excited to be advancing our third abuse deterrent technology into clinical testing. If successful, we believe the oral abuse deterrent capabilities of LIMITX will mark a significant advancement in the field of opioid abuse deterrence."

LIMITX Hydromorphone is being developed in part with a grant from the National Institute on Drug Abuse (NIDA). NIDA is not responsible for the results of any of the research.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation.

Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, whether the FDA will raise questions on our IND and delay our commencement of Study AP-LTX-400, the expected results of Study AP-LTX-400 and the date by which such study results will be available, whether LIMITX will retard the release of opioid active ingredients as dose levels increase, our ability to fund or to obtain funding for our continued operations, the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties, and the ability of our patents to protect our products from generic competition, our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation, our and our licensee's ability to successfully launch and commercialize our products and technologies including OXAYDO Tablets and NEXAFED products, the price and price discounting that may be offered by Egalet for OXAYDO, our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies and the market acceptance of and competitive environment for any of our products, the willingness of pharmacies to stock our NEXAFED products, expectations regarding potential market share for our products, our ability to enter into additional license agreements for our other product candidates, our exposure to product liability and other lawsuits in connection with the commercialization of our products, the increased cost of insurance and the availability of product liability insurance coverage, and the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates, including our LIMITX product candidates, and the sufficiency of our development to meet over-the-counter, or OTC, Monograph standards as applicable, the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, whether the FDA will agree with our analysis of our clinical and laboratory studies and how it may evaluate the results of these studies or whether further studies of our product candidates will be required to support FDA approval, whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies, whether our product candidates formulated with our Aversion or LIMITX technologies will ultimately deter abuse in commercial settings and whether our Impede technology will disrupt the processing of pseudoephedrine into methamphetamine. In some cases, you can identify forward- looking statements by terms such as "may," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," Predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

DILAUDID is a trademark of Purdue Pharma L.P.

Contact: for Acura Investor Relations Email contact 847-705-7709 Renmark Financial Communications Inc. Robert Thaemlitz Email contact Media D. Elizabeth Culley Email contact (416) 644-2020 (514) 939-3989 www.renmarkfinancial.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 46

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 0

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 78

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 52

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 12

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 23

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading

Top 5 Most Recently Viewed Articles

White Castle Introduces Unbeatable $4 Deal for Sliders

Updated Category News Views 212

White Castle Launches Exclusive $4 Slider Offer Beginning May 9, White Castle is rolling out an enticing promotion: six Original Sliders for just $4. This limited-time offer brings the price of the sliders below what customers paid back in 2012, making it a fantastic opportunity for those seeking budget-friendly meal options. The price breakdown amounts to less than 67...

Continue Reading
Alienware Revives Iconic Area-51 Gaming System for Fans

Updated Category News Views 423

Alienware Reintroduces Area-51 Systems Alienware, a brand known for pushing the boundaries of gaming hardware, is thrilled to announce the comeback of the legendary Area-51. This fan-favorite line has been revitalized, now available in both desktop and laptop versions, ensuring that gamers can enjoy cutting-edge performance in their preferred format. Rich History of...

Continue Reading
LifeStance Health Group's Impressive Q2 2025 Performance Highlights

Updated Category News Views 227

LifeStance Reports Strong Financial Performance in Q2 2025 LifeStance Health Group, Inc. (NASDAQ: LFST), a leading provider of outpatient mental healthcare across the United States, has showcased its robust growth with the release of its financial results for the second quarter of 2025. This period witnessed LifeStance achieving remarkable revenue growth alongside...

Continue Reading
First Financial Corporation Announces New Dividend Update

Updated Category News Views 127

First Financial Corporation's Latest Dividend Declaration The directors of First Financial Corporation (NASDAQ: THFF) have made an exciting announcement regarding their quarterly dividend. The company declared a dividend of 51 cents per share. This payment will provide a valuable return for shareholders and is scheduled to be paid out shortly. A record of shareholders...

Continue Reading
Desjardins Expands Commitment to Affordable Housing Units by 2028

Updated Category News Views 267

Desjardins Group's Pledge for Affordable Housing In response to the urgent housing crisis, Desjardins Group is taking bold steps to address the pressing need for affordable housing. They recently announced an ambitious plan to construct over 10,000 affordable and deferred-affordability housing units aimed at assisting families, students, and individuals who are struggling...

Continue Reading